These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30709769)

  • 1. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
    Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
    EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
    Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Hessmann E; Patzak MS; Klein L; Chen N; Kari V; Ramu I; Bapiro TE; Frese KK; Gopinathan A; Richards FM; Jodrell DI; Verbeke C; Li X; Heuchel R; Löhr JM; Johnsen SA; Gress TM; Ellenrieder V; Neesse A
    Gut; 2018 Mar; 67(3):497-507. PubMed ID: 28077438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
    Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J
    Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
    Basu R; Kulkarni P; Swegan D; Duran-Ortiz S; Ahmad A; Caggiano LJ; Davis E; Walsh C; Brenya E; Koshal A; Brody R; Sandbhor U; Neggers SJCMM; Kopchick JJ
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B; Xing F; Wang J; Wang X; Zhou C; Fan G; Zhuo Q; Ji S; Yu X; Xu X; Qin Y; Li Z
    Cancer Lett; 2024 Oct; 602():217197. PubMed ID: 39216548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.